Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

TELO Total Debt

Short-term and long-term borrowings combined.

Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt rises 117.1% from a year ago

Total debt stood at $202.87K at the end of Q1 FY2026, up 117.1% from a year earlier and down 57.2% from the prior quarter. Over 3 fiscal years it compounded at -6.6% a year.

Context

  • Total debt amounted to 3.5% of total assets at the end of Q1 FY2026, down 15.5 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.

What to watch

Whether total debt keeps rising in the next quarterly balance sheet after a +117.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$202.87K-57.2% QoQ
Last fiscal yearDec 2025
$473.75K+407.1% YoY
Year agoMar 2025
$93.43K+117.1% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+117.1%——
1 year+407.1%——
3-year CAGR-6.6%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
473.75K USD
Year-over-year change
+407.1%

Total Debt vs competitors

How TELO compares with its peers on the latest reported figures

  • TELO's Mar 2026 total debt of $202.87K is the 5th highest of the 6 companies compared; the peer median is $1.51M.
  • Its year-over-year change of +117.1% is the 3rd highest of 6, against a peer median of +23.7%.
  • Total debt amounts to 3.5% of total assets for TELO, versus a peer median of 5.8%.
TELO Competitors Peer median
Total Debt for TELO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KPTIKaryopharm Therapeutics Inc.Mar 2026$230.87M +23.7%+9.3%175.7%
IPSCCentury Therapeutics, Inc.Mar 2026$48.03M -8.8%-4.1%14.7%
INMBINmune Bio, Inc.Mar 2026$1.51M +335.2%-59.3%5.8%
EQEquillium, Inc.Mar 2026$692K +134.6%-58.7%1.1%
TELOTelomir Pharmaceuticals, Inc. Common StockMar 2026$202.87K +117.1%-6.6%3.5%
COEPCoeptis Therapeutics, Inc.Mar 2026$100K -95.1%-49.2%0.5%
Peer median (excluding TELO) $1.51M+23.7%-49.2%5.8%

Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents01.42K1.23K1.27M7.29M
Short-term Investments00000
Net Receivables00130K00
Inventory00000
Other Current Assets047.31K303.28K0(0)
Total Current Assets048.73K435.23K1.32M7.34M
Property, Plant & Equipment (Net)00000
Goodwill00000
Intangible Assets00000
Long-term Investments55K0000
Tax Assets00000
Other Non-current Assets004.34M00
Total Non-current Assets55K04.34M00
Total Assets55K48.73K4.77M1.32M7.34M
Account Payables18.74K404.22K707.19K587.54K536.77K
Short-term Debt0581.79K101K93.43K473.75K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities119.4K581.79K527.38K00
Total Current Liabilities138.13K986.01K1.34M680.97K1.43M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0(0)000
Total Non-current Liabilities0(0)000
Total Liabilities138.13K986.01K1.34M680.97K1.43M
Common Stock00000
Retained Earnings(138.13K)(992.28K)(14.06M)(30.6M)(41.01M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(83.13K)(937.28K)3.44M643.04K5.91M
Total Debt0581.79K101K93.43K473.75K
Net Debt119.4K580.37K99.77K(1.17M)(6.81M)

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.